1.34
-0.16(-10.67%)
Currency In USD
| Previous Close | 1.5 |
| Open | 1.5 |
| Day High | 1.51 |
| Day Low | 1.23 |
| 52-Week High | 5.67 |
| 52-Week Low | 0.6 |
| Volume | 4.43M |
| Average Volume | 1.73M |
| Market Cap | 46.34M |
| PE | -1.24 |
| EPS | -1.08 |
| Moving Average 50 Days | 1.37 |
| Moving Average 200 Days | 1.72 |
| Change | -0.16 |
If you invested $1000 in Reviva Pharmaceuticals Holdings, Inc. (RVPH) since IPO date, it would be worth $138 as of December 21, 2024 at a share price of $1.34. Whereas If you bought $1000 worth of Reviva Pharmaceuticals Holdings, Inc. (RVPH) shares 5 years ago, it would be worth $128.11 as of December 21, 2024 at a share price of $1.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
GlobeNewswire Inc.
Dec 17, 2024 3:25 AM GMT
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of
Reviva Announces Proposed Public Offering
GlobeNewswire Inc.
Dec 16, 2024 10:18 PM GMT
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
GlobeNewswire Inc.
Dec 16, 2024 1:00 PM GMT
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full data set from open-label extension